Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for KYTX is 17.68M, and currently, shorts hold a 13.47% of that float. The average trading volume for KYTX on September 26, 2024 was 471.86K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KYTX) stock’s latest price update
Kyverna Therapeutics Inc. (NASDAQ: KYTX)’s stock price has dropped by -6.26 in relation to previous closing price of 5.59. Nevertheless, the company has seen a loss of -20.61% in its stock price over the last five trading days. prnewswire.com reported 2024-09-18 that Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101’s initial efficacy and safety profile and broad potential in B cell-driven neuroinflammatory diseases Key biomarkers indicate potential for KYV-101 to durably modify neuroinflammatory diseases with immune system reset Kyverna to present posters on design and methods for company-sponsored clinical trials in neuroinflammatory diseases EMERYVILLE, Calif., Sept. 18, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the presentation of three posters outlining the design and methods of Kyverna’s clinical trials evaluating KYV-101 in neuroinflammatory diseases at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, taking place September 18-20, 2024.
KYTX’s Market Performance
Kyverna Therapeutics Inc. (KYTX) has experienced a -20.61% fall in stock performance for the past week, with a -37.54% drop in the past month, and a -27.92% drop in the past quarter. The volatility ratio for the week is 9.57%, and the volatility levels for the past 30 days are at 7.80% for KYTX. The simple moving average for the past 20 days is -26.29% for KYTX’s stock, with a -65.67% simple moving average for the past 200 days.
Analysts’ Opinion of KYTX
Many brokerage firms have already submitted their reports for KYTX stocks, with H.C. Wainwright repeating the rating for KYTX by listing it as a “Neutral.” The predicted price for KYTX in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on July 03, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see KYTX reach a price target of $44. The rating they have provided for KYTX stocks is “Overweight” according to the report published on March 04th, 2024.
Morgan Stanley gave a rating of “Overweight” to KYTX, setting the target price at $40 in the report published on March 04th of the current year.
KYTX Trading at -32.58% from the 50-Day Moving Average
After a stumble in the market that brought KYTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.05% of loss for the given period.
Volatility was left at 7.80%, however, over the last 30 days, the volatility rate increased by 9.57%, as shares sank -34.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.66% lower at present.
During the last 5 trading sessions, KYTX fell by -20.61%, in comparison to the 20-day moving average, which settled at $6.97. In addition, Kyverna Therapeutics Inc. saw -82.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYTX starting from Vida Ventures, LLC, who purchase 253,136 shares at the price of $22.00 back on Feb 12 ’24. After this action, Vida Ventures, LLC now owns 252,553 shares of Kyverna Therapeutics Inc., valued at $5,568,992 using the latest closing price.
Bain Capital Life Sciences Inv, the 10% Owner of Kyverna Therapeutics Inc., purchase 450,000 shares at $22.00 during a trade that took place back on Feb 12 ’24, which means that Bain Capital Life Sciences Inv is holding 3,163,868 shares at $9,900,000 based on the most recent closing price.
Stock Fundamentals for KYTX
The total capital return value is set at -0.3.
Based on Kyverna Therapeutics Inc. (KYTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.94. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -558.07.
Currently, EBITDA for the company is -58.47 million with net debt to EBITDA at 1.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.86.
Conclusion
In conclusion, Kyverna Therapeutics Inc. (KYTX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
